

Award Number: **W81XWH-12-1-0523**

TITLE: Complement Activation Alters Platelet Function

PRINCIPAL INVESTIGATOR: George Tsokos, M.D.

**CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center
Boston, MA**

REPORT DATE: October 2014

TYPE OF REPORT: Annual

**PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012**

**DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited**

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2014		2. REPORT TYPE annual		3. DATES COVERED 30 Sep 2013 – 29 Sep 2014	
4. TITLE AND SUBTITLE Complement Activation Alters Platelet Function				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0523	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) George Tsokos, M.D. E-Mail: gtsokos@bidmc.harvard.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Beth Israel Deaconess Medical Center 330 Brookline Avenue Boston, MA 02215-5491				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We have established base line criteria that will allow us to evaluate the role of platelets during trauma. These studies have started to unravel the relationship between platelets and complement and their contribution to tissue damage. It seems that complement C3 does not deposit on the surface of platelets following ischemia/reperfusion. Yet, we have seen the deposition of both C3 and platelets in various tissues following IRI in a similar time frame. Further studies will evaluate if these factors co-localize in tissue. We have developed B6.lprPF4-/- mice which will allow us to better study the role of PF4 in tissue damage. Preliminary studies indicate a decreased level of platelets in these mice, suggesting a decreased level of disease. Further studies will expand upon these observations better outlining the function of platelets in the injury associated with trauma. Ultimately these studies will allow us to develop specific treatment strategies that limit battlefield tissue injury without affecting haemostatic and coagulation properties of platelets.					
15. SUBJECT TERMS Platelets, Complement, Trauma, Tissue Damage					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	13	19b. TELEPHONE NUMBER (include area code)

Table of Contents

W81XWH-12-1-0523

Introduction.....	4
Body.....	5
Key Research Accomplishments.....	12
Reportable Outcomes.....	12
Conclusion.....	12
References.....	13

Introduction

The primary function of platelets is the maintenance of hemostasis, antimicrobial host defense and tissue repair (Klinger and Jelkmann, 2002). Platelets are the smallest and most abundant blood cell type found in the circulation. Activation of platelets in response to injury initiates an inflammatory response resulting in platelet aggregation, expression of adhesion molecule receptors and co-stimulatory molecules such as P-selectin (CD62P), CD40, and CD154 as well as release of cytokines such as interleukin-1 beta (IL-1 β) and transforming growth factor-beta 1 (TGF β 1) (Elzey et al., 2003; Klinger and Jelkmann, 2002; Soslau et al., 1997).

While platelets are traditionally thought to be regulators of hemostasis and coagulation, there is mounting evidence that they may also be important in the development and progression of inflammatory processes (Coppinger et al., 2004; Danese et al., 2003). Recent studies have demonstrated a role for platelets in the development of both innate and adaptive immune responses (Elzey et al., 2003; Shiraki et al., 2004). Platelets have also been shown to participate directly in the immune response through interaction with vascular endothelium, with antigen presenting cells (APC) and with lymphocytes, or through the release of soluble mediators that include pro-inflammatory cytokines, cell adhesion molecules or chemokines (Elzey et al., 2003). Platelets have also been shown to actively participate in ongoing inflammatory responses such as those observed in atherosclerosis, arthritis and inflammatory bowel disease (Danese et al., 2003). Nonetheless, it is not clear by what mechanisms platelets may be involved in the progression of cellular or tissue injury after severe trauma. Activated platelets and platelet-derived microparticles (PMPs) may participate in specific receptor-ligand interactions through co-stimulatory molecules such as CD40-CD154, or adhesion molecules CD62P-CD162 (PSGL-1) interaction (Elzey et al., 2003). Conversely, activated T cells or APC may stimulate platelets through similar receptor-ligand interactions and/or through exposure to cytokines including IL-6, other acute-phase reactants, and pro-coagulant factors such as thrombin (Elzey et al., 2003; Klinger and Jelkmann, 2002; Soslau et al., 1997).

The complement system comprises more than 30 proteins that interact in proteolytic cascades with three initiating arms. The classical, lectin, and alternative pathways are each activated by distinct mechanisms: antibodies initiate the classical pathway, while mannose-binding lectin and bacterial polysaccharides initiate the lectin and alternative pathways, respectively. Each initiating arm produces the enzymatic complexes, C3 and C5 convertases. The cleavage of C3 and C5 advances the cascade in all three pathways, culminating in a common terminal arm, the membrane attack complex (MAC; C5b-9). MAC inserts into the membrane of target cells, forming a pore that result in cell lysis. In addition to cell lysis, the complement cascade also increases phagocytosis, generates inflammatory molecules that recruit inflammatory cells, and it instructs the adaptive immune system to produce appropriate humoral responses (Thurman and Holers, 2006). The complement pathways initiated during trauma have not been well defined.

Activated platelets can exist in either pro-aggregatory or pro-inflammatory states (Kulkarni et al., 2007). Thus, platelets have the capacity to respond to diverse systemic stimuli that include complement fragments, nucleotides, cytokines, integrins, adhesion molecules, and co-stimulatory molecules. Hence, differences in the kinetics and extent of platelet responses depend on the type and concentrations of stimuli encountered. The overall goal of the following series of experiments is to advance our understanding of the beneficial or detrimental role of platelets in trauma patients. We will evaluate the protective and destructive effects of platelets and of their products in our models of ischemia/reperfusion (IR) injury, and hemorrhagic shock (HS). This will allow us to develop specific treatment strategies that limit battlefield tissue injury without affecting haemostatic and coagulation properties of platelets.

Body

2.4 Determine whether active Syk is required for the release of CXCL4 into the lungs.

Previous studies in our group identified the importance of PF4 in ischemia-reperfusion injury. PF4 deposition in tissue is increased following IRI and in the absence of PF4 (B6.PF4^{-/-} mice) less tissue damage is observed after IRI (Lapchak et al., 2012). Since it is known that B6.lpr mice exhibit greater tissue damage following IRI as compared to wild type mice (Fleming et al., 2004), we have backcrossed the B6.PF4^{-/-} mice with B6.lpr mice to assess if the absence of PF4 will alleviate the tissue damage observed in these mice following IRI. Furthermore, these mice will be used alongside the B6.PF4^{-/-} in our platelet adoptive transfer model.

Since T cells play a key role in mediating tissue damage, we assessed the presence of Naïve T cells and Double Negative T cells in this knock out mouse model. Preliminary results show that B6.lprPF4^{-/-} mice have more Naïve T cells and less Double Negative T cells than B6.lpr mice. This suggests that the absence of PF4 alleviates some tissue damage in the lupus prone mice.

Figure 1. B6.lprPF4^{-/-} mice show more Naïve T cells than B6.lpr mice




Figure 2. B6.lprPF4^{-/-} mice have less double negative T cells than B6.lpr mice.





Figure 3. B6.lprPF4 ^{-/-} mice have less T cell infiltration into the Kidney than B6.lpr mice.




Goal 3. Determine whether platelets from trauma patients are decorated with complement and whether this results in altered function.

3.1. Determine whether complement deposits on the surface of platelets from trauma patients.


We optimized the condition to isolate platelets from human whole peripheral blood and stained them for CD41 (population marker). We also optimized the conditions for platelet activation by thrombin and measured CD62P by flow cytometry. Thrombin activated platelets will serve as a positive control for our further experiments to study complement deposition on the surface of platelets.

Fig 4. Panel **A**. The gated population represents platelets. Panel **B**. Platelets stained with CD41
Panel **C**. Activated platelets with thrombin stained with CD62


A.



B.




C.



We then isolated platelets from whole peripheral blood, collected from healthy donors as well as patients presented to the emergency room after a localized trauma. Deposition of complement on platelets was evaluated by flow cytometry using monoclonal antibodies to C4d, C4d neo, C3a, C3d, C1q. As shown in a representative sample, trauma platelets have more C4d neo, C4d, and C3a deposition compared to healthy platelets (Fig 5).


Fig 5. Complement deposition on trauma vs healthy platelets.



3.2. Determine whether serum from trauma patients can decorate healthy platelets with complement.

Platelets were isolated from whole peripheral blood and collected from healthy donors. Isolated platelets were incubated with serum, obtained from healthy donors as well as patients presented to emergency room after a localized trauma. The platelets were then washed and incubated with monoclonal antibody to C4d, C3d, and C1q. Deposition of complement on platelets was evaluated by flow cytometry. Figure 6, **Panel A** illustrated cumulative data of C4d deposition on the healthy Platelets incubated with trauma serum(n=20) and normal serum(n=11). **Panel B** is a representative data illustrating deposition of C4d , and C3a on platelets from healthy donors after incubation with either normal or trauma serum . As shown in a representative sample, trauma serum promotes C4d and C3a deposition on healthy platelets.


Figure 6. Complement deposition on healthy platelets after incubation with normal vs trauma serum.



3.3 Determine whether trauma serum alters ability of healthy platelet aggregation

We have shown that serum collected from trauma patients has more complement activation than serum from healthy donors. As it was demonstrated in previous figure trauma sera specifically decorates platelet with more C4d and C3a. Ability of trauma serum to affect platelets aggregation is an unknown territory and of clinical relevance. It is possible that complement deposition on platelet by sera is responsible for this alteration. To further establish the effect of trauma serum on platelets, healthy platelets aggregation was measure in respond to TRAP (Platelet aggregator) after 1 hr incubation with normal vs trauma serum by aggregometer. In Figure 7 we have shown that incubation of healthy platelets with trauma serum decreases their ability to aggregate. Panel A is a representative and Panel B is accumulative data.

3.4 Determine whether complement in trauma serum which decorates healthy platelets alters their aggregation. Further investigation of the role of complement, trauma serum was depleted from C4d and incubated with healthy platelets. We have found healthy platelets incubated with depleted C4d trauma serum aggregate less than the one incubated with trauma serum. It seems complement activation in serum increases the ability of platelets to aggregate. (fig 7)



Key Research Accomplishments

Trauma platelets have more C4d neo, C4d, and C3a deposition compared to healthy platelets.

Incubation of healthy platelets with trauma serum decreases their ability to aggregate.

Syk inhibition decreases platelet lodging in the lungs indicating Syk is integral in platelet sequestration and organ damage.

Crossing B6.lpr mice with PF4^{-/-} mice may alleviate multi organ dysfunction in Lupus prone mice.

Reportable Outcomes

Nothing to report

Conclusions

We have established base line criteria that will allow us to evaluate the role of platelets during trauma. These studies have started to unravel the relationship between platelets and complement and their contribution to tissue damage. It seems that complement C3 does not deposit on the surface of platelets following ischemia/reperfusion. Yet, we have seen the deposition of both C3 and platelets in various tissues following IRI in a similar time frame. We have developed B6.lprPF4^{-/-} mice which will allow us to better study the role of PF4 in tissue damage. Preliminary studies indicate a decreased level of platelets in these mice. We have also provided studies suggesting that the decrease of platelets in these mice alleviate multi organ dysfunction in lupus models. We have evaluated the relationship between Syk and platelets and have thus far identified a role for Syk in platelet lodging in tissue. Further studies will expand upon these observations better outlining the function of platelets in the injury associated with trauma.

Ultimately these studies will allow us to develop specific treatment strategies that limit battlefield tissue injury without affecting haemostatic and coagulation properties of platelets.

References

1. Coppinger, J.A., G. Cagney, S. Toomey, T. Kislinger, O. Belton, J.P. McRedmond, D.J. Cahill, A. Emili, D.J. Fitzgerald, and P.B. Maguire. 2004. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. *Blood* 103:2096-2104.
2. Danese, S., C. de la Motte, A. Sturm, J.D. Vogel, G.A. West, S.A. Strong, J.A. Katz, and C. Fiocchi. 2003. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. *Gastroenterology* 124:1249-1264.
3. Elzey, B.D., J. Tian, R.J. Jensen, A.K. Swanson, J.R. Lees, S.R. Lentz, C.S. Stein, B. Nieswandt, Y. Wang, B.L. Davidson, and T.L. Ratliff. 2003. Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. *Immunity* 19:9-19.
4. Fleming, S.D., M. Monestier, and G.C. Tsokos. 2004. Accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. *Journal of immunology* 173:4230-4235.
5. Klinger, M.H., and W. Jelkmann. 2002. Role of blood platelets in infection and inflammation. *Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research* 22:913-922.
6. Kulkarni, S., K.J. Woollard, S. Thomas, D. Oxley, and S.P. Jackson. 2007. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. *Blood* 110:1879-1886.
7. Lapchak, P.H., A. Ioannou, P. Rani, L.A. Lieberman, K. Yoshiya, L. Kannan, J.J. Dalle Lucca, M.A. Kowalska, and G.C. Tsokos. 2012. The role of platelet factor 4 in local and remote tissue damage in a mouse model of mesenteric ischemia/reperfusion injury. *PloS one* 7:e39934.
8. Shiraki, R., N. Inoue, S. Kawasaki, A. Takei, M. Kadotani, Y. Ohnishi, J. Ejiri, S. Kobayashi, K. Hirata, S. Kawashima, and M. Yokoyama. 2004. Expression of Toll-like receptors on human platelets. *Thrombosis research* 113:379-385. 11
9. Soslau, G., D.A. Morgan, J.S. Jaffe, I. Brodsky, and Y. Wang. 1997. Cytokine mRNA expression in human platelets and a megakaryocytic cell line and cytokine modulation of platelet function. *Cytokine* 9:405-411
10. Thurman, J.M., and V.M. Holers. 2006. The central role of the alternative complement pathway in human disease. *Journal of immunology* 176:1305-1310.